CN108785250A - A kind of compound amino acid suspension and preparation method thereof for treating, preventing livestock and poultry acute and chronic renal failure - Google Patents
A kind of compound amino acid suspension and preparation method thereof for treating, preventing livestock and poultry acute and chronic renal failure Download PDFInfo
- Publication number
- CN108785250A CN108785250A CN201710681776.8A CN201710681776A CN108785250A CN 108785250 A CN108785250 A CN 108785250A CN 201710681776 A CN201710681776 A CN 201710681776A CN 108785250 A CN108785250 A CN 108785250A
- Authority
- CN
- China
- Prior art keywords
- parts
- amino acid
- renal failure
- compound amino
- chronic renal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 compound amino acid Chemical class 0.000 title claims abstract description 57
- 239000000725 suspension Substances 0.000 title claims abstract description 54
- 244000144972 livestock Species 0.000 title claims abstract description 36
- 244000144977 poultry Species 0.000 title claims abstract description 36
- 230000001154 acute effect Effects 0.000 title claims abstract description 31
- 208000020832 chronic kidney disease Diseases 0.000 title claims abstract description 29
- 208000022831 chronic renal failure syndrome Diseases 0.000 title claims abstract description 29
- 208000009304 Acute Kidney Injury Diseases 0.000 title claims abstract description 28
- 208000033626 Renal failure acute Diseases 0.000 title claims abstract description 28
- 201000011040 acute kidney failure Diseases 0.000 title claims abstract description 28
- 208000012998 acute renal failure Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 229940024606 amino acid Drugs 0.000 claims abstract description 80
- 235000001014 amino acid Nutrition 0.000 claims abstract description 80
- 150000001413 amino acids Chemical class 0.000 claims abstract description 40
- 239000004094 surface-active agent Substances 0.000 claims abstract description 18
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 17
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 17
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004472 Lysine Substances 0.000 claims abstract description 17
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004473 Threonine Substances 0.000 claims abstract description 17
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 17
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229930182817 methionine Natural products 0.000 claims abstract description 17
- 239000000375 suspending agent Substances 0.000 claims abstract description 17
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 16
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 16
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003755 preservative agent Substances 0.000 claims abstract description 16
- 230000002335 preservative effect Effects 0.000 claims abstract description 16
- 239000004474 valine Substances 0.000 claims abstract description 16
- 239000004475 Arginine Substances 0.000 claims abstract description 15
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 15
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 15
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 14
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 14
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 13
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960000310 isoleucine Drugs 0.000 claims abstract description 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000018417 cysteine Nutrition 0.000 claims abstract description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 14
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 14
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 14
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 14
- HVUMOYIDDBPOLL-UHFFFAOYSA-N 2-(3,4-Dihydroxyoxolan-2-yl)-2-hydroxyethyl octadecanoate Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)C1OCC(O)C1O HVUMOYIDDBPOLL-UHFFFAOYSA-N 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 12
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 11
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 11
- 244000125380 Terminalia tomentosa Species 0.000 claims description 11
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 11
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 11
- 229920000053 polysorbate 80 Polymers 0.000 claims description 11
- 239000006188 syrup Substances 0.000 claims description 11
- 235000020357 syrup Nutrition 0.000 claims description 11
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 10
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 10
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 10
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 9
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 9
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 9
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 9
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 9
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 9
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 9
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 9
- 229940101027 polysorbate 40 Drugs 0.000 claims description 9
- 229940113124 polysorbate 60 Drugs 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 8
- 239000000084 colloidal system Substances 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 229920000609 methyl cellulose Polymers 0.000 claims description 8
- 235000010981 methylcellulose Nutrition 0.000 claims description 8
- 239000001923 methylcellulose Substances 0.000 claims description 8
- 235000010413 sodium alginate Nutrition 0.000 claims description 8
- 239000000661 sodium alginate Substances 0.000 claims description 8
- 229940005550 sodium alginate Drugs 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 235000010489 acacia gum Nutrition 0.000 claims description 7
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 150000003871 sulfonates Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 20
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract description 8
- 239000002245 particle Substances 0.000 abstract description 7
- 235000013599 spices Nutrition 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 235000013594 poultry meat Nutrition 0.000 description 23
- 241000287828 Gallus gallus Species 0.000 description 12
- 235000013330 chicken meat Nutrition 0.000 description 12
- 238000000034 method Methods 0.000 description 8
- 208000001647 Renal Insufficiency Diseases 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 201000006370 kidney failure Diseases 0.000 description 7
- 239000000654 additive Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 229930193140 Neomycin Natural products 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 208000001889 Acid-Base Imbalance Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000259759 Cassida nobilis Species 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a kind of compound amino acid suspensions and preparation method for treating, preventing livestock and poultry acute and chronic renal failure, and wherein compound amino acid suspension includes following component；At least one of histidine, cysteine, tryptophan, threonine, lysine, arginine, glutamine, valine, methionine, isoleucine, phenylalanine, leucine；Surfactant, suspending agent, preservative, compound amino acid suspension of the invention can be diluted with the water of arbitrary proportion, be administered orally for livestock and poultry.Using cryogenic high pressure homogeneous technology, make the particle diameter distribution for the amino acid for not allowing the Yishui River between 100-300 nanometers, increases amino acid absorption in vivo and utilization rate；And are greatly saved by manpower, facilitates Clinical practice, group is particularly suitable for and is administered on a large scale because the treatment of disease or drug-induced acute and chronic renal failure, effect and convenience are better than the administration of Chinese medicine spice for clinical livestock and poultry.
Description
Technical field
The present invention relates to animal health technical fields, and in particular to a kind of for treating, preventing livestock and poultry acute and chronic renal failure
Compound amino acid suspension and preparation method thereof.
Background technology
Renal failure is divided into the course of disease and pathologically：Acute renal failure and chronic kidney hypofunction.Acute renal failure is glomerular filtration
The clinical syndrome that function declines rapidly suddenly.Classical symptom die-offed with acute urine volume, electric matter is disorderly and acid-base imbalance and
It is unable to excretion metabolism product；Blood urea nitrogen and serum creatinine increase rapidly and cause and acute symptoms of uremia.Chronic renal failure is
The disease that 70% or more the reduction of kidney function energy unit absolute quantity, the various clinical symptoms generated therefrom and metabolic disorder are formed
Hou Qun.Caused by the chronic kidney hypofunction mainly use of infection and inflammatory disease and drug.It influences to have caused by body broken
Bad organismic internal environment relative equilibrium, metabolite and noxious material are detained in vivo, water, salt and disturbance of acid-base balance, continue nitrogen
Mass formed by blood stasis exists, and causes multiple organs failure.
In the breeding process, happening occasionally for renal failure occurs for livestock and poultry, caused by the bacterium infection other than, the use of drug
The renal failure of livestock and poultry can be caused to occur.Livestock and poultry are needed drug to be prevented, are thus more aggravated to kidney due to the infection of bacterium
Dirty damage.If livestock and poultry are in breeding process, the disease of enteron aisle is often suffered from.Currently, the treatment common drug of intestines problem is amino
Glucoside antibiotic, as neomycin, kanamycins etc..It is this kind of that especially kidney is more toxic, easily cause the damage of kidney.
Lack of standardization additionally, due to Clinical practice drug, large dosage, overdose also be easy to cause the damage to kidney using chemical classes drug.
The death rate for directly resulting in livestock and poultry increases, and reduces the control effect of drug, wastes a large amount of human and material resources and financial resources.Therefore, face
Spice is carried out using some Chinese medicine preparations on bed, to alleviate the damage because of disease and drug to livestock and poultry kidney.But Chinese medicine preparation
It needs to be added in feed in use, there are big inconveniences when use.
Invention content
In order to solve above-mentioned insufficient defect, the present invention provides a kind of for treating, preventing livestock and poultry acute and chronic renal failure
Compound amino acid suspension and preparation method thereof can be diluted with the water of arbitrary proportion, is administered orally for livestock and poultry.Utilize low temperature height
Homogeneous technology is pressed, makes the particle diameter distribution for the amino acid for not allowing the Yishui River between 100-300 nanometers, increases amino acid in vivo
Absorption and utilization rate；And for clinical livestock and poultry because of the treatment of disease or drug-induced acute and chronic renal failure, effect and just
Profit better than Chinese medicine spice be administered, be greatly saved manpower, facilitate Clinical practice, be particularly suitable for group on a large scale to
Medicine.
The present invention provides a kind of compound amino acid suspensions for treating, preventing livestock and poultry acute and chronic renal failure, including with
Lower component；
Histidine, cysteine, tryptophan, threonine, lysine, arginine, glutamine, valine, methionine,
At least one of isoleucine, phenylalanine, leucine；
Surfactant, suspending agent, preservative.
Above-mentioned compound amino acid suspension, wherein further include solvent, it is preferably single to steam water or purified water.
Above-mentioned compound amino acid suspension, wherein the surfactant is sorbester p18, span 40, span 85, tween
20, in polysorbate40, polysorbate60, Tween 80, dodecyl sodium sulfate, glycerin monostearate, polyoxyethylene laurel ether at least
It is a kind of.
Above-mentioned compound amino acid suspension, wherein the suspending agent is glycerine, syrup, sodium carboxymethylcellulose, methyl
Cellulose, hydroxypropyl cellulose, carbomer, Arabic gum, xanthans, sodium alginate, at least one of PVP k30.
Above-mentioned compound amino acid suspension, wherein the preservative is methyl hydroxybenzoate, ethylparaben, nipalgin
At least one of propyl ester.
Above-mentioned compound amino acid suspension, wherein the content of amino acid is 3-8g/ in compound amino acid suspension
100mL。
Above-mentioned compound amino acid suspension, wherein the raw material composition including following parts by weight：0-5 parts of histidine, half Guang
0-5 parts of propylhomoserin, 0-5 parts of tryptophan, 3-9 parts of threonine, 6-12 parts of lysine, 0-10 parts of arginine, 0-5 parts of glutamine, figured silk fabrics
3-9 parts of propylhomoserin, 1-10 parts of methionine, 0-9 parts of isoleucine, 1-12 parts of phenylalanine, 3-12 parts of leucine, sorbester p18 0-
20 parts, span 40 be 0-40 parts, span 85 is 0-20 parts, polysorbas20 is 0-40 parts, polysorbate40 is 0-30 parts, polysorbate60 0-20
Part, Tween 80 be 0-20 parts, 0-2 parts of dodecyl sodium sulfate, 0-5 parts of glycerin monostearate, polyoxyethylene laurel ether 0-6
Part, glycerine are 0-20 parts, syrup is 0-30 parts, sodium carboxymethylcellulose is 0-5 parts, methylcellulose is 0-5 parts, hydroxypropyl is fine
Dimension element is 0-5 parts, carbomer is 0-5 parts, Arabic gum is 0-10 parts, xanthans is 0-10 parts, sodium alginate is 0-10 parts,
PVP k30 be 0-5 parts, 0-1 parts of methyl hydroxybenzoate, 0-1 parts of ethylparaben, 0-1 parts of propylben.
Above-mentioned compound amino acid suspension, wherein the raw material composition including following parts by weight：
2 parts of histidine, Cys2 part, 0.1 part of tryptophan, 9 parts of threonine, 12 parts of lysine, 10 parts of arginine, paddy
1 part of glutamine, 9 parts of valine, 1 part of methionine, 9 parts of isoleucine, 1 part of phenylalanine, 10 parts of leucine, Tween 80 10
Part, syrup is 10 parts, 3 parts of sodium carboxymethylcellulose, 1 part of methyl hydroxybenzoate.
Above-mentioned compound amino acid suspension, wherein the raw material composition including following parts by weight：2 parts of histidine, tryptophan
3 parts, 9 parts of threonine, 12 parts of lysine, 10 parts of arginine, 1 part of glutamine, 9 parts of valine, 10 parts of methionine, phenylpropyl alcohol ammonia
12 parts of acid, sorbester p18 are 10 parts, and polyoxyethylene laurel ether is 6 parts, and Arabic gum is 3 parts, 3 parts of sodium carboxymethylcellulose, Ni Bo
0.3 part of tortoise beetle ester, 0.7 part of ethylparaben.
The another side of the present invention, a kind of system for treating, preventing the compound amino acid suspension of livestock and poultry acute and chronic renal failure
Preparation Method includes the following steps：
By different types of amino acid, surfactant, suspending agent, preservative is pre-processed by colloid mill；
It will be mixed to get to compound amino acid through the pretreated mixed liquor of colloid mill is high-pressure homogeneous under conditions of 2-7 DEG C
Suspension, wherein high-pressure homogeneous specific method is mixture is first passed through to colloid mill in advance handle preliminary to prepare amino acid mixing
Thing liquid body, then under 4 DEG C of water bath conditions, under 60Mbar pressure, recycle 10 times and prepare amino acid complex suspension.Prepared
Amino acid complex oral solution, the particle diameter distribution of amino acid are can be uniformly dispersed between 100-300 nanometers, 1500rpm centrifugations
Without precipitation, cryogenic high pressure homogeneous technology is utilized so as to realize, makes the particle diameter distribution for the amino acid for not allowing the Yishui River within 15 minutes
Between 100-300 nanometers, amino acid absorption in vivo and utilization rate are increased.
The present invention has the following advantages：1, it can dilute with the water of arbitrary proportion, be administered orally for livestock and poultry；2, low temperature is utilized
High pressure homogenization technique makes the particle diameter distribution for the amino acid for not allowing the Yishui River between 100-300 nanometers, increases amino acid in vivo
Absorption and utilization rate；3, for clinical livestock and poultry because of the treatment of disease or drug-induced acute and chronic renal failure, effect and just
Profit Chinese medicine spice is administered, and is greatly saved manpower, facilitates Clinical practice, is particularly suitable for group and is administered on a large scale.
Specific implementation mode
In the following description, a large amount of concrete details are given in order to provide more thorough understanding of the invention.So
And it is obvious to the skilled person that the present invention may not need one or more of these details and be able to
Implement.In other examples, in order to avoid with the present invention obscure, for some technical characteristics well known in the art not into
Row description.
In order to thoroughly understand the present invention, detailed step and detailed structure will be proposed in following description, so as to
Illustrate technical scheme of the present invention.Presently preferred embodiments of the present invention is described in detail as follows, however other than these detailed descriptions, this
Invention can also have other embodiment.
Embodiment 1, a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure, including with the following group
Part；
Histidine, cysteine, tryptophan, threonine, lysine, arginine, glutamine, valine, methionine,
At least one of isoleucine, phenylalanine, leucine；
Surfactant, suspending agent, preservative.
Embodiment 2, a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure, including with the following group
Part；
Histidine, cysteine, tryptophan, threonine, lysine, arginine, glutamine, valine, methionine,
At least one of isoleucine, phenylalanine, leucine；
Surfactant, suspending agent, preservative, wherein surfactant be sorbester p18, span 40, span 85, polysorbas20,
At least one in polysorbate40, polysorbate60, Tween 80, dodecyl sodium sulfate, glycerin monostearate, polyoxyethylene laurel ether
Kind.
Embodiment 3, a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure, including with the following group
Part；
Histidine, cysteine, tryptophan, threonine, lysine, arginine, glutamine, valine, methionine,
At least one of isoleucine, phenylalanine, leucine；
Surfactant, suspending agent, preservative, wherein surfactant be sorbester p18, span 40, span 85, polysorbas20,
At least one in polysorbate40, polysorbate60, Tween 80, dodecyl sodium sulfate, glycerin monostearate, polyoxyethylene laurel ether
Kind, wherein suspending agent is glycerine, syrup, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl cellulose, carbomer, Arab
Glue, xanthans, sodium alginate, at least one of PVP k30.
Embodiment 4, a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure, including with the following group
Part；
Histidine, cysteine, tryptophan, threonine, lysine, arginine, glutamine, valine, methionine,
At least one of isoleucine, phenylalanine, leucine；
Surfactant, suspending agent, preservative, wherein surfactant be sorbester p18, span 40, span 85, polysorbas20,
At least one in polysorbate40, polysorbate60, Tween 80, dodecyl sodium sulfate, glycerin monostearate, polyoxyethylene laurel ether
Kind, wherein suspending agent is glycerine, syrup, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl cellulose, carbomer, Arab
Glue, xanthans, sodium alginate, at least one of PVP k30, wherein preservative are methyl hydroxybenzoate, ethylparaben, Ni Bo
At least one of golden propyl ester.
Embodiment 5, a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure, including with the following group
Part；
Histidine, cysteine, tryptophan, threonine, lysine, arginine, glutamine, valine, methionine,
At least one of isoleucine, phenylalanine, leucine；
Surfactant, suspending agent, preservative, wherein surfactant be sorbester p18, span 40, span 85, polysorbas20,
At least one in polysorbate40, polysorbate60, Tween 80, dodecyl sodium sulfate, glycerin monostearate, polyoxyethylene laurel ether
Kind, wherein suspending agent is glycerine, syrup, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl cellulose, carbomer, Arab
Glue, xanthans, sodium alginate, at least one of PVP k30, wherein preservative are methyl hydroxybenzoate, ethylparaben, Ni Bo
At least one of golden propyl ester, the content of amino acid is 3-8g/100mL wherein in compound amino acid suspension, further preferably
For 5g/100mL.
Embodiment 6, a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure, including it is following heavy
Measure the raw material composition of part：0-5 parts of histidine, 0-5 parts of cysteine, 0-5 parts of tryptophan, 3-9 parts of threonine, lysine 6-12
Part, 0-10 parts of arginine, 0-5 parts of glutamine, 3-9 parts of valine, 1-10 parts of methionine, 0-9 parts of isoleucine, phenylpropyl alcohol ammonia
1-12 parts sour, 3-12 parts of leucine, sorbester p18 are 0-20 parts, span 40 is 0-40 parts, span 85 is 0-20 parts, polysorbas20 0-
40 parts, polysorbate40 be 0-30 parts, polysorbate60 is 0-20 parts, Tween 80 is 0-20 parts, 0-2 parts of dodecyl sodium sulfate, single stearic
0-5 parts of acid glyceride, polyoxyethylene laurel ether are 0-6 parts, glycerine is 0-20 parts, syrup is 0-30 parts, sodium carboxymethylcellulose
For 0-5 parts, methylcellulose be 0-5 parts, hydroxypropyl cellulose is 0-5 parts, carbomer is 0-5 parts, Arabic gum is 0-10 parts,
Xanthans is 0-10 parts, sodium alginate is 0-10 parts, PVP k30 are 0-5 parts, 0-1 parts of methyl hydroxybenzoate, ethylparaben 0-1
Part, 0-1 parts of propylben.
Several specific embodiments are provided again below
Embodiment 7, a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure, including it is following heavy
Measure the raw material composition of part：Take 2 parts of histidine, Cys2 part, 0.1 part of tryptophan, 9 parts of threonine, 12 parts of lysine, smart ammonia
10 parts of acid, 1 part of glutamine, 9 parts of valine, 1 part of methionine, 9 parts of isoleucine, 1 part of phenylalanine, 10 parts of leucine,
It is mixed well.Suitable purified water is taken, is 10 parts to middle addition Tween 80, syrup is 10 parts, sodium carboxymethylcellulose 3
Part, 1 part of methyl hydroxybenzoate.Ispol 5g is taken, the purified water containing surfactant, suspending agent, preservative is added to
In, and purified water is supplemented to 100mL.According to this ratio, the mixing liquid for the appropriate volume worked good is first passed through into colloid mill
It is pre-processed, can reach requirement by 3 times colloid mills.It is carried out pretreated with high pressure homogenizer containing amino-acid liquid
Homogeneous.High-pressure homogeneous method recycles 10 times under 4 DEG C of water-baths, 60Mbar pressure.Prepared amino acid complex mouth
Liquid is taken, the particle diameter distribution of amino acid is can be uniformly dispersed between 100-300 nanometers, and 1500rpm centrifuges 15 minutes without heavy
It forms sediment.
Embodiment 8, a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure, including it is following heavy
Measure the raw material composition of part：Take 2 parts of histidine, 3 parts of tryptophan, 9 parts of threonine, 12 parts of lysine, 10 parts of arginine, glutamine
1 part, 9 parts of valine, 10 parts of methionine, 12 parts of phenylalanine mixed well.Suitable purified water is taken, to middle addition
Sorbester p18 is 10 parts, and polyoxyethylene laurel ether is 6 parts, and Arabic gum is 3 parts, 3 parts of sodium carboxymethylcellulose, methyl hydroxybenzoate
0.3 part, 0.7 part of ethylparaben.Take ispol 5g, be added to containing surfactant, suspending agent, preservative it is pure
Change in water, and supplements purified water to 100mL.According to this ratio, the mixing liquid for the appropriate volume worked good is first passed through into glue
Body mill is pre-processed, and can reach requirement by 3 times colloid mills.By pretreated high pressure homogenizer containing amino-acid liquid
Carry out homogeneous.High-pressure homogeneous method recycles 10 times under 4 DEG C of water-baths, 60Mbar pressure.Prepared amino acid is compound
Object oral solution, the particle diameter distribution of amino acid are can be uniformly dispersed between 100-300 nanometers, no precipitation.
Embodiment 9, the pathology modeling for carrying out acute renal failure to mouse by mercury chloride, the amino prepared by embodiment 7
Sour suspension carries out oral curative effect experiment.By the amino acid suspension in embodiment 7, suitable single steaming water is added, by amino acid
Suspension dilutes 250 times.Refrigerator cold-storage restores in use, taking out in advance to room temperature.Kunming mouse 70 is bought, in laboratory
After adaptability examination is supported 3 days, the mouse 50 for selecting 18-22 grams of weight is only grouped, every group 10, half male and half female.Before attacking poison, prohibit
Food prohibits water 12 hours.In addition to feminine gender is organized, remaining each group is according to the weight of 6mg/kg, intraperitoneal injection mercuric chloride solution (1mg/mL).
Drinking-water is freely eaten after attacking poison, it is negative, positive that the physiological saline that control group every feeds 0.2mL, drug are not administered after 24 hours
Control group feeds dexamethasone according to 0.2mg/kg weight and 6mg/kg weight feeds every 0.2mL of Verapamil, and amino acid is mixed
Suspension group feeds the suspension after amino acid dilution according to every mouse 0.2mL.Normally feeding is drunk water during experiment, is filled on day 3
It is fed for after medicine terminates 12 hours, the mouse of survival is weighed, etherization, broken end takes blood.Blood is centrifuged through 4000rpm
5min takes serum to be detected.Test result is as shown in table 1 below：
1 amino acid tablet of table causes mercury chloride the therapeutic effect of chmice acute renal failure
Embodiment 10
Feidong County large size pig farm, in 4000 weanling pigs, has 32 breathing problem, clinical symptoms table occur
It is now that body temperature increases, respiratory symptom occurs in swinery, has difficulty in breathing, breathes.Swinery spirit is depressed, poor appetite, and drink is intended to increase.
32 pigs of this morbidity are isolated, every 8 are divided into a circle, totally 4 circle.Common therapeutic scheme is, with pioneer IV and fluorine Buddhist nun
Pungent meglumine injection progress intramuscular injection, continuous 5 days.To 2 circle therein, added in Chinese drugs dispensing renal function in first feed
Powdered medicine is fed.In addition 2 circles, the amino acid suspension in embodiment 7 is added into drinking-water, 50 are watered according to 100mL
Kilogram, allow pig free water, entire treatment cycle to be 5 days.Test result is as shown in table 2 below.
2. amino acid suspension of table prevents pig the experiment of renal failure
From table 2 it can be seen that the cure rate of amino acid drinking-water group is higher than Chinese medicine additive group, the death rate is also below in
Medicine additive group.Pathological anatomy is carried out to 3 pigs dead in Chinese medicine additive group, analysis wherein has 2 head-kidneys are dirty to occur not
With the lesion of degree.Illustrate compound amino acid suspension of the invention for clinical pig because of disease or drug-induced acute and chronic
The treatment of renal failure, effect and convenience are superior to the administration of Chinese medicine spice.The death rate for reducing pig improves drug to disease
Control effect, save a large amount of human and material resources and financial resources.Prepared amino acid suspension can directly be watered dilution, face
Bed is easy to use.
Embodiment 11
Feixi raiser has 20,000 plumage blueness foot fiber crops chickens, colibacillosis has occurred in 17 age in days.Clinical symptoms table
It is now that spirit is depressed, loose random, body is become thin.Just start dead 50 daily, finally progressively increases to more than 100.Pathology
Dissect finds that packet packet liver, air bag are muddy.It is detached through bacterium, selects neomycin to carry out clinical treatment after drug sensitive test.Selection one
6000 chickens group of henhouse is tested.This henhouse is separated from the middle, both sides are 3000 about each.Whole henhouse is upper and lower
Noon is drunk water with neomycin, every time limit drink 2 hours, prohibits water 2 hours before administration every time.After neomycin is administered in the afternoon, this henhouse one
Partly use the water of the suspension containing amino acid in embodiment 8 instead, specific method is that the amino acid suspension of 100mL is watered 200 public affairs
Jin, always second day early morning of free water.In addition half adds the traditional Chinese powder medicine of prevention renal failure into feed, carries out feeding and gives
Medicine.Test period is 5 days, and test result is as shown in table 3 below.
3. amino acid suspension of table prevents chicken the experiment of renal failure
It is found by experiment that, the The dead quantity of Chinese medicine additive group chicken is more than 2 times of amino acid drinking-water group quantity.It is treating
After 3 days, the whole recovery of the chicken group of amino acid drinking-water group is better than Chinese medicine additive group.After treatment 3 days, amino acid drink
Chicken group in water group is not further continued for the phenomenon that chicken death occur.When treating the 5th day, Chinese medicine group just stops chicken and death occurs
The phenomenon that.Dissect comparison is carried out to dead chicken to find, in addition to answering Escherichia coli to cause the cause of death of chicken, amino acid drinking-water group
Renal lesions degree and quantity that lesion occur to be less than Chinese medicine additive group.The compound amino acid suspension pair of the present invention
In Prevention clinic chicken because the treatment of disease or drug-induced acute and chronic renal failure, effect and convenience are superior to Chinese medicine
Spice is administered.The death rate for reducing chicken improves control effect of the drug to disease, save a large amount of human and material resources and
Financial resources.Prepared amino acid suspension can directly be watered dilution, and the group that Clinical practice is conveniently suitable for fowl is administered on a large scale.
Presently preferred embodiments of the present invention is described above.It is to be appreciated that the invention is not limited in above-mentioned
Particular implementation, wherein the equipment and structure be not described in detail to the greatest extent are construed as giving reality with the common mode in this field
It applies；Any technical person familiar with the field, without departing from the scope of the technical proposal of the invention, all using the disclosure above
Methods and technical content many possible changes and modifications are made to technical solution of the present invention, or be revised as equivalent variations etc.
Embodiment is imitated, this is not affected the essence of the present invention.Therefore, every content without departing from technical solution of the present invention, foundation
The technical spirit any simple modifications, equivalents, and modifications made to the above embodiment of the present invention, still fall within the present invention
In the range of technical solution protection.
Claims (9)
1. a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure, which is characterized in that including with the following group
Part；
It is histidine, cysteine, tryptophan, threonine, lysine, arginine, glutamine, valine, methionine, different bright
At least one of propylhomoserin, phenylalanine, leucine；
Surfactant, suspending agent, preservative.
2. a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure as described in claim 1, special
Sign is that the surfactant is sorbester p18, span 40, span 85, polysorbas20, polysorbate40, polysorbate60, Tween 80,12
At least one of sodium alkyl sulfonate, glycerin monostearate, polyoxyethylene laurel ether.
3. a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure as claimed in claim 2, special
Sign is, the suspending agent be glycerine, syrup, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl cellulose, carbomer, Ah
Draw primary glue, xanthans, sodium alginate, at least one of PVP k30.
4. a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure as described in claim 1, special
Sign is that the preservative is at least one of methyl hydroxybenzoate, ethylparaben, propylben.
5. a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure as claimed in claim 4, special
Sign is that the content of amino acid is 3-8g/100mL in compound amino acid suspension.
6. a kind of compound amino acid for treating, preventing livestock and poultry acute and chronic renal failure as described in any one in claim 1-5 is mixed
Suspension, which is characterized in that the raw material composition including following parts by weight：0-5 parts of histidine, 0-5 parts of cysteine, tryptophan 0-5
Part, 3-9 parts of threonine, 6-12 parts of lysine, 0-10 parts of arginine, 0-5 parts of glutamine, 3-9 parts of valine, methionine 1-
10 parts, 0-9 parts of isoleucine, 1-12 parts of phenylalanine, 3-12 parts of leucine, sorbester p18 be 0-20 parts, span 40 is 0-40 parts,
Span 85 is 0-20 parts, polysorbas20 is 0-40 parts, polysorbate40 is 0-30 parts, polysorbate60 is 0-20 parts, Tween 80 is 0-20 parts, ten
0-2 parts of dialkyl sulfonates, 0-5 parts of glycerin monostearate, polyoxyethylene laurel ether are 0-6 parts, glycerine is 0-20 parts, syrup
For 0-30 parts, sodium carboxymethylcellulose be 0-5 parts, methylcellulose is 0-5 parts, hydroxypropyl cellulose is 0-5 parts, carbomer is
0-5 parts, Arabic gum be 0-10 parts, xanthans is 0-10 parts, sodium alginate is 0-10 parts, PVP k30 are 0-5 parts, nipalgin
0-1 parts of methyl esters, 0-1 parts of ethylparaben, 0-1 parts of propylben.
7. a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure as claimed in claim 6, special
Sign is, includes the raw material composition of following parts by weight：
2 parts of histidine, Cys2 part, 0.1 part of tryptophan, 9 parts of threonine, 12 parts of lysine, 10 parts of arginine, glutamy
1 part of amine, 9 parts of valine, 1 part of methionine, 9 parts of isoleucine, 1 part of phenylalanine, 10 parts of leucine, Tween 80 are 10 parts,
Syrup is 10 parts, 3 parts of sodium carboxymethylcellulose, 1 part of methyl hydroxybenzoate.
8. a kind of compound amino acid suspension for treating, preventing livestock and poultry acute and chronic renal failure as claimed in claim 6, special
Sign is, includes the raw material composition of following parts by weight：2 parts of histidine, 3 parts of tryptophan, 9 parts of threonine, 12 parts of lysine, smart ammonia
10 parts of acid, 1 part of glutamine, 9 parts of valine, 10 parts of methionine, 12 parts of phenylalanine, sorbester p18 are 10 parts, polyoxyethylene
Bay ether is 6 parts, and Arabic gum is 3 parts, 3 parts of sodium carboxymethylcellulose, 0.3 part of methyl hydroxybenzoate, 0.7 part of ethylparaben.
9. a kind of preparation method for treating, preventing the compound amino acid suspension of livestock and poultry acute and chronic renal failure, which is characterized in that
Include the following steps：
By different types of amino acid, surfactant, suspending agent, preservative is pre-processed by colloid mill；
It will be high-pressure homogeneous to get to compound amino acid suspension under conditions of 2-7 DEG C through the pretreated mixed liquor of colloid mill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710681776.8A CN108785250A (en) | 2017-08-10 | 2017-08-10 | A kind of compound amino acid suspension and preparation method thereof for treating, preventing livestock and poultry acute and chronic renal failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710681776.8A CN108785250A (en) | 2017-08-10 | 2017-08-10 | A kind of compound amino acid suspension and preparation method thereof for treating, preventing livestock and poultry acute and chronic renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108785250A true CN108785250A (en) | 2018-11-13 |
Family
ID=64094513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710681776.8A Pending CN108785250A (en) | 2017-08-10 | 2017-08-10 | A kind of compound amino acid suspension and preparation method thereof for treating, preventing livestock and poultry acute and chronic renal failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108785250A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112190543A (en) * | 2020-08-11 | 2021-01-08 | 河北科星药业有限公司 | Compound amino acid oral solution for dogs and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823766A (en) * | 2006-03-30 | 2006-08-30 | 胡正岳 | Compound amino acid vitamin dispersion tablet and its preparation method |
| CN101933900A (en) * | 2009-07-02 | 2011-01-05 | 天津瑞普生物技术股份有限公司 | Compound preparation for preventing and treating poultry liver diseases and preparation method thereof |
| WO2015076631A1 (en) * | 2013-11-25 | 2015-05-28 | 경희대학교 산학협력단 | Composition for preventing or treating growth disorders, containing malt extracts |
-
2017
- 2017-08-10 CN CN201710681776.8A patent/CN108785250A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823766A (en) * | 2006-03-30 | 2006-08-30 | 胡正岳 | Compound amino acid vitamin dispersion tablet and its preparation method |
| CN101933900A (en) * | 2009-07-02 | 2011-01-05 | 天津瑞普生物技术股份有限公司 | Compound preparation for preventing and treating poultry liver diseases and preparation method thereof |
| WO2015076631A1 (en) * | 2013-11-25 | 2015-05-28 | 경희대학교 산학협력단 | Composition for preventing or treating growth disorders, containing malt extracts |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112190543A (en) * | 2020-08-11 | 2021-01-08 | 河北科星药业有限公司 | Compound amino acid oral solution for dogs and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6448001B2 (en) | Liquid formulation | |
| CN1265560A (en) | Composition and method for curing diabetes | |
| CN105748420B (en) | A kind of preparation method of LCZ696 sustained-release matrix tablets that treating heart failure | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| CN105193707A (en) | Ambroxol hydrochloride oral solution and preparation method thereof | |
| CN101862293B (en) | Doxycycline hydrochloride oil turbid liquor, preparation method and application thereof | |
| CN105412128B (en) | Treat the pharmaceutical composition and its preparation process of osteoarthritis | |
| CN104661680B (en) | Compound and its influence to appetite control and insulin sensitivity | |
| CN108785250A (en) | A kind of compound amino acid suspension and preparation method thereof for treating, preventing livestock and poultry acute and chronic renal failure | |
| Zhang et al. | Intestinal microbiology and metabolomics of streptozotocin-induced type 2 diabetes mice by polysaccharide from Cardamine violifolia | |
| CN108815150A (en) | It is a kind of to treat dog cat acute and chronic renal failure compound amino acid piece and preparation method thereof | |
| CN103520111B (en) | A kind of florfenicol dry suspension and its production and use | |
| CN102283842A (en) | Compound mequindox florfenicol nanoemulsion antibacterial drug and preparation method thereof | |
| CN102552250B (en) | Compound amino acid injection for livestock as well as preparation method and applications thereof | |
| CN102166239B (en) | Product for preventing and/or treating diabetes | |
| JP2011057585A (en) | Antidepressant agent | |
| WO2022237731A1 (en) | Pharmaceutical composition for treating hyperlipidemia and preparation method therefor | |
| KR102256847B1 (en) | Compositions and methods for chronic use of a weight-gaining compound | |
| WO2021212700A1 (en) | Pharmaceutical composition for improving motion sickness of pets, preparation method therefor and use method thereof | |
| RU2392944C2 (en) | Preparation for treatment and prevention of selenium metabolism disorder for farm animals | |
| CN104784152B (en) | A kind of Thiamphenicol micro-capsule and preparation method and application | |
| CN105663107B (en) | Compound amino acid capsule agent | |
| CN110448562A (en) | Application of the lupenone in preparation treatment renal damage drug | |
| CN110831590A (en) | Medicine containing pemfibrate | |
| WO2022036800A1 (en) | Compound amino acid enteric-coated capsule for dog, and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181113 |